Experimental Lilly Antibody Drug Neutralizes Omicron in Vitro

By Reuters Staff

January 11, 2022

(Reuters) - An experimental monoclonal antibody treatment from Eli Lilly & Co is effective against all known variants of the coronavirus, including Omicron, researchers have found.

The drug, known as LY-CoV1404 or bebtelovimab, "potently" neutralized engineered versions of numerous variants, including Alpha, Beta, Delta, Epsilon, Gamma, Iota, and Omicron, in test tube experiments, the researchers reported on Friday on bioRxiv ahead of peer review.

They noted that an experimental antibody drug from GlaxoSmithKline and Vir Biotechnology called sotrovimab also neutralizes Delta and Omicron, but said that bebtelovimab "is equally effective in viral neutralization against all tested variants and is several-fold more potent." That could potentially allow for lower doses and injection under the skin rather than intravenous administration.

A spokesperson for Eli Lilly said the company is "urgently working with the FDA to make bebtelovimab available under an emergency use authorization and expect authorization" during the current quarter of 2022.

SOURCE: https://bit.ly/3r86RtF bioRxiv, online January 7, 2022.